Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amorphous calcium carbonate - Amorphical

Next Previous
Drug Profile

Amorphous calcium carbonate - Amorphical

Alternative Names: ACC - Amorphical; AMOR-1; AMOR-18; Amorphous calcium carbonate (ACC) - Amorphical; Nanoparticulate amorphous calcium carbonate - Amorphical

Latest Information Update: 09 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amorphical
  • Class Anti-infectives; Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Crohn's disease; Hypocalcaemia; Pancreatic cancer
  • Phase I/II COVID 2019 infections

Most Recent Events

  • 19 Dec 2025 Amorphical files for patent protection for ACC as a means of treating DMD and an aid for in-vitro fertilization (IVF) and improving sperm quality in multiple countries (Amorphical Website, December 2025).
  • 19 Dec 2025 Amorphical has patent protection for ACC for aiding athletes, Production methods at commercial scale, ACC for improving the extracorporeal growth of vital cells in Undisclosed location (Amorphical Website, December 2025)
  • 19 Dec 2025 Amorphical has patent protection for for treatment of cancer, neurological disorders, muscular disorders, lung diseases, pain, nutritional disorders, bone disorders, fertility disorders, autoimmune diseases, Alzheimer’s disease and dementia in US, Europian union, Japan, China, Canada and Israel (Amorphical Website, December 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top